record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
GD2-CAR T cell therapy for H3K27M-mutated gliomas (Nature, s41586-022-04489-4)
authors
reviewer:will-blair
GD2-CAR T-cell therapy (IV followed by intracerebroventricular dosing) induced volumetric tumor regression >50% in 5/11 H3K27M glioma patients, durable complete response in 1/11, and sustained survival >2 years in several participants with median OS improvement over historical controls
vs_7d2942ba6e79cdad · manual_curation
outgoing
vf_7f6da3752d579c3dGD2-CAR T cells show durable responses in H3K27M-mutant gliomas where conventional therapies fail, suggesting immunotherapy complements non-immunologic modalities
events
vev_0cd389d1be10f834finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_ced6dd0bf5203dcefinding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.